Ashraful I Khan Selected Research

Cholera Toxin

1/2019	Posttranslational Regulation of IL-23 Production Distinguishes the Innate Immune Responses to Live Toxigenic versus Heat-Inactivated Vibrio cholerae.
1/2016	O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh.
5/2010	Concomitant enterotoxigenic Escherichia coli infection induces increased immune responses to Vibrio cholerae O1 antigens in patients with cholera in Bangladesh.
1/2010	Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh.
1/2010	Comparison of clinical features and immunological parameters of patients with dehydrating diarrhoea infected with Inaba or Ogawa serotypes of Vibrio cholerae O1.
9/2009	Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh.
1/2009	Immunologic responses to Vibrio cholerae in patients co-infected with intestinal parasites in Bangladesh.
10/2008	Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1.
4/2008	Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh.
11/2005	Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ashraful I Khan Research Topics

Disease

28	Cholera 07/2021 - 08/2004
23	Infections 07/2021 - 08/2004
6	Diarrhea 01/2021 - 10/2008
4	Dehydration (Water Stress) 05/2016 - 01/2006
1	Inflammation (Inflammations) 01/2022
1	Reinfection 01/2019
1	Convalescence 01/2016
1	Communicable Diseases (Infectious Diseases) 12/2011
1	Vomiting 11/2009
1	Anemia 07/2006
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2006
1	Measles 01/2006

Drug/Important Bio-Agent (IBA)

13	AntigensIBA 01/2017 - 08/2004
11	Immunoglobulin G (IgG)IBA 01/2021 - 04/2008
11	Immunoglobulin A (IgA)IBA 01/2021 - 08/2004
11	Cholera ToxinIBA 01/2019 - 08/2005
11	LipopolysaccharidesIBA 01/2018 - 04/2008
6	O Antigens (O Antigen)IBA 07/2021 - 05/2014
5	VaccinesIBA 05/2016 - 08/2005
4	Blood Group Antigens (Blood Groups)IBA 01/2021 - 11/2005
4	Biomarkers (Surrogate Marker)IBA 01/2021 - 04/2008
4	AntibodiesIBA 11/2020 - 08/2004
4	Cholera Vaccines FDA Link 01/2019 - 05/2014
4	Immunoglobulin M (IgM)IBA 01/2018 - 01/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 11/2009
3	Vitamin A (Retinol)FDA LinkGeneric 11/2008 - 01/2006
2	Proteins (Proteins, Gene)FDA Link 01/2017 - 09/2009
2	EnzymesIBA 09/2009 - 10/2008
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022
1	IronIBA 01/2021
1	16S Ribosomal RNAIBA 01/2021
1	Monoclonal AntibodiesIBA 11/2020
1	Interleukin-23 (Interleukin 23)IBA 01/2019
1	NADPH Oxidases (NAD(P)H oxidase)IBA 01/2018
1	Dual OxidasesIBA 01/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2018
1	InterferonsIBA 01/2018
1	Interferon Regulatory Factor-7 (Interferon Regulatory Factor 7)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 01/2018
1	shancholIBA 05/2016
1	Polysaccharides (Glycans)IBA 01/2016
1	4-O-carboxymethylascochlorinIBA 11/2012
1	ABO Blood-Group SystemIBA 12/2011
1	Lewis Blood Group AntigensIBA 12/2011
1	lipopolysaccharide AIBA 11/2009
1	ZincIBA 11/2008
1	MicronutrientsIBA 11/2008
1	Immunoglobulins (Immunoglobulin)IBA 10/2008
1	Ferritins (Ferritin)IBA 07/2006
1	Hemoglobins (Hemoglobin)IBA 07/2006
1	Capsules (Microcapsules)IBA 01/2006

Therapy/Procedure

2	Fluid Therapy (Oral Rehydration Therapy) 01/2018 - 04/2011
1	Bathroom Equipment 01/2015
1	Therapeutics 04/2011
1	Chemoprevention 11/2009